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Jugular venous thrombosis is unusual and is associated with central venous catheterisation, intravenous drug abuse and head and
neck sepsis. It is rarely associated with malignancy. We report a case of metastatic carcinoma of unknown primary in a forty year
old female which presented with jugular venous thrombosis. The discussion includes investigation and treatment options for this
condition.
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1.Introduction
Historically jugular venous thrombosis has been associated
with head and neck sepsis but has become increasingly
uncommon since the introduction of antibiotics. According
to Espritus and Media [1] central venous catheterisation
and intravenous drug abuse are the most common aetio-
logical factors recognised in current practice. Jugular venous
thrombosis may also arise secondary to malignancy, and this
association, although rare, should be considered in patients
who present with this condition [2].
In this paper we describe a case of metastatic carcinoma
of unknown primary which presented with a jugular venous
thrombosis together with suggested investigation pathway
and treatment options.
2.CaseReport
A-40-year old female, previously ﬁt and well, presented
with pain and swelling of the left side of her neck of four
days duration, in association with a sore throat and chest
tightness. The pain radiated to the left axilla and shoulder.
There was no history of fever or night sweats, and she had
lost about 8lbs in weight in the previous 3months. She had
no cough, and clinical history was otherwise unremarkable.
She had no relevant past medical or surgical history and was
not taking any medications.
On examination, there was diﬀuse tender swelling on the
left side of neck with marked engorgement of the superﬁcial
veins over this area, also involving the upper part of chest
and upper left arm. There were a few scattered small tender
lymph nodes in the posterior triangle of the left side of the
neck. The remainder of clinical examination was normal.
Initial laboratory investigations showed a normal full
blood count, with a raised erythrocyte sedimentation rate of
58mm and elevated C-reactive protein of 45units (normal
range is 0–10units). Urea and electrolytes, liver function
tests,andthyroidfunctiontestswerenormal,andchestX-ray
wasalsounremarkable.Athrombophiliascreenwasnegative,
and serum ANA was weakly positive.
She was referred initially for ultrasound examination of
theneckwhichdemonstratedextensivethrombosisoftheleft
internal and external jugular veins (Figures 1(a) and 1(b)).
Ultrasound also demonstrated enlarged lymph nodes
in the left supraclavicular fossa which were suspicious of
malignancy (Figure 2).
She was initially treated with intravenous antibiotics and
was anticoagulated with low molecular weight heparin fol-
lowed by warfarin. Subsequently she underwent computed
tomography (CT) of the neck, chest, abdomen, and pelvis2 Case Reports in Medicine
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Figure 1:TransversecolourDopplersonogramshowingleftinternaljugularvein(IJV-arrow)containingthrombusandnocolourﬂow.Note
the normal colour ﬂow in common carotid artery (CCA). Longitudinal colour Doppler sonogram showing thrombosed left IJV (arrows).
Figure 2:Sonogramofleftsupraclavicularfossashowingmalignant
left supraclavicular adenopathy.
which conﬁrmed venous thrombosis of the left jugular veins.
CT also showed multiple enlarged left supraclavicular nodes,
an enlarged right retro-crural lymph node, and extensive
portal and para-aortic adenopathy extending down to the
aortic bifurcation (Figure 3).
No other lesions were demonstrated, with the liver and
lungs in particular appearing normal.
This patient underwent an incisional biopsy of a left
supraclavicular lymph node under general anaesthesia. The
histology revealed replacement of normal node architecture
by metastatic poorly diﬀerentiated carcinoma with probable
squamoid diﬀerentiation. In order to ﬁnd out the primary
site she underwent panendoscopy of her upper aerodigestive
tract which was normal. Further investigations failed to
establish a possible primary site. This included gynae-
cological and pelvic examinations, proctosigmoidoscopy,
tumour marker study, and CT scan of paranasal sinuses.
Figure 3: Axial postcontrast CT image at the level of the kidneys
demonstrating extensive para-aortic lymphadenopathy (arrows).
A subsequent positron emission tomography also failed to
identify a primary site malignancy.
With a diagnosis of metastatic carcinoma of unknown
primary, she was referred to the oncology department. She
showed an initial response to chemotherapy and remained
well at 6months followup.
3. Discussion
Venous thrombosis usually aﬀects the legs. The veins in the
head and neck are less susceptible to thrombosis as they are
mostly valveless and their drainage is aided by gravity in the
upright position.
Data relating to the natural history of jugular venous
thrombosis is lacking. The prevalence rate for past or active
malignancy as a risk factor for internal jugular venous
thrombosis has been reported to be 29.7% [3]. Isolated
jugular venous thrombosis is usually asymptomatic, whereas
subclavian and axillary venous thrombosis produces pain
and arm swelling [4].
Thecausesofjugularveinthrombosismaybelocalorsys-
temic. Local factors include infections of paranasal sinuses,
otological, facial, or orodental infections and local invasionCase Reports in Medicine 3
by tumour encroaching the veins. Infective causes have been
reduced signiﬁcantly due to the use of antibiotics. In current
everyday practice the more commonly recognised causes are
central venous catheters, haemodialysis, and pacemakers. Of
these, central venous catheter (CVC) associated thrombosis
is the leading cause of jugular thrombosis.
Systemic factors for jugular venous thrombosis include
conditions that predispose to a hypercoagulable state [5].
These include thrombogenic disorders, myeloproliferative
disorders, oestrogen use, pregnancy and the postpartum
period, and malignancies.
The incidence of venous thromboembolism is higher
in cancer patients because of a combination of risk factors
like host hypercoagulability, chemotherapy, immobilization,
and insertion of CVCs. Long-term CVCs often facilitate
chemotherapy, transfusions, parenteral nutrition, and blood
sampling. However, vessel injury, venous stasis, and cancer
related hypercoagulability increase the risk for CVC-related
deep vein thrombosis. The incidence of clinically overt
catheter associated upper-limb deep vein thrombosis has
been reported to vary between 0.3% and 28.3% [6]. The
incidence of clinically overt pulmonary embolism in such
patients ranges from 15% to 25%.
The association between malignancy and thrombo-
phlebitic events was ﬁrst described by Armond Trousseau
where migratory thrombophlebitis was associated with gas-
tric carcinoma [7]. It is thought that tumour cells activate
the blood coagulation system either by directly stimulating
thrombin formation [8] or by inducing mononuclear cells to
synthesize procoagulants such as tissue factors, prothrombin
activators, and factor 5 activators. Cancer cells may also
mediate platelet aggregation or activate endothelial cells by
certain cytokines (TNF, IL-1) to generate substances that
stimulate the production of coagulation tissue factors [9].
Pulmonary Embolism is a life threatening complication
of jugular venous thrombosis and has been observed in 2.7%
of cases [3]. Other complications include septic emboli, sep-
ticaemia, cerebral oedema, and pseudotumour cerebri [4].
Theinitialinvestigationsshouldincludefullbloodcount,
urea and electrolytes, liver function tests, clotting proﬁle,
thrombophilia, screen and tumour marker study.
Ultrasonography is an excellent diagnostic method for
jugular venous thrombosis with an average sensitivity of 97
percent [10] and is the initial imaging modality of choice for
delineation of venous thrombosis in both the deep veins of
the leg and the neck. Venography is rarely used nowadays as
it is invasive and involves contrast injection and exposure to
radiation. Computed tomography and magnetic resonance
venography have not yet been established. These modalities
are however used to demonstrate adjacent structures in the
neck, and to stage malignant disease. Although scanning
describes the invasive properties of a speciﬁc mass, a biopsy
often combined with upper aero digestive tract endoscopy is
essential to establish a deﬁnitive diagnosis.
Treatment of jugular venous thrombosis includes anti-
coagulation with low molecular weight heparin followed
by warfarin to prevent thromboembolic events. Superior
venacaval ﬁlters are rarely indicated in isolated jugular
venous thrombosis. However they can be used in patients
with contraindication to anticoagulation. Other treatment
modalities depend on individual cases and include use of
antibiotics in the setting of infection, removal of central
venous catheters, and appropriate chemo irradiation for
malignant tumours. Jugular venous thrombosis due to deep
neck infections may require drainage of ﬂuid collections and
local debridement.
The treatment of CVC-associated thrombosis should be
based on the prolonged use of low molecular weight heparin,
except in the event of severe renal impairment when it
shouldbebasedontheuseofunfractionatedheparin,rapidly
replaced by warfarin [11]. Clinicians should be aware of
the interaction between warfarin and 5-ﬂuorouracil because
of a high incidence of INR abnormalities and consequent
bleeding risk [12].
Isolated case series discuss the use of thrombolytic drugs
(streptokinase, urokinase, recombinant tissue plasminogen
activator) in the treatment of CVC-associated thrombosis
[13, 14]. Thrombolytic drugs are considered only in speciﬁc
conditions where the thrombotic risk is higher than the risk
associated with the use of these drugs, that is, in the event of
vena cava syndrome [11].
There is insuﬃcient evidence available on the value of
catheter removal in CVC associated thrombosis. However,
there is a real risk of embolisation during or immediately
after catheter removal [1]. The catheter can be retained
if it is mandatory, functional, in the right position and
uninfected. In this case an anticoagulation treatment should
be maintained as long as the catheter is retained [11]. The
catheter removal is warranted in situations like malposition,
infected thrombus, and irreversible occlusion of the lumen.
4. Conclusion
Jugular venous thrombosis may be ﬁrst manifestation of an
occult malignancy and may be due to the hyper coagulated
state of the patient secondary to a metastatic malignancy.
In the absence of an obvious head and neck pathology or
haematologicaldisorder,disseminatedmalignancyshouldbe
suspected and further investigations initiated.
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